Ipilimumab/Nivolumab Not Superior to Chemotherapy in Gastric Cancer

Outcomes were not better with ipilimumab plus nivolumab in patients with CPS >5% and in all randomized patients.

Regulatory approval was granted for first-line use of nivolumab combined with FOLFOX in metastatic gastroesophageal cancer based on results of the industry-sponsored, phase 3 CHECKMATE 649 trial. The trial demonstrated improvements in response, progression-free survival (PFS), and overall survival (OS) at 12-month follow up in the target population of patients with programmed cell death-ligand 1 (PDL-1) combined positive scores (CPS) >5% and in all patients treated (NEJM JW Oncol Hematol Aug 2021 and Lancet 2021; 398:27). There is ongoing debate about the utility of nivolumab in patients with low or negative expression of PDL-1.

Investigators now report updated results from CHECKMATE 649 at a minimum follow up of 24 months, including finding…

Reviewing Author

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

Ipilimumab/Nivolumab Not Superior to Chemotherapy in Gastric Cancer

Topics

Reviewing Author